title: Cognitive performance in healthy women during induced hypogonadism and ovarian steroid addback.
abstract: Gynecology clinic-based studies have consistently demonstrated that induced hypogonadism is accompanied by a decline in cognitive test performance. However, a recent study in healthy asymptomatic controls observed that neither induced hypogonadism nor estradiol replacement influenced cognitive performance. Thus, the effects of induced hypogonadism on cognition might not be uniformly experienced across individual women. Moreover, discrepancies in the effects of hypogonadism on cognition also could suggest the existence of specific risk phenotypes that predict a woman's symptomatic experience during menopause. In this study, we examined the effects of induced hypogonadism and ovarian steroid replacement on cognitive performance in healthy premenopausal women. Ovarian suppression was induced with a GnRH agonist (Lupron) and then physiologic levels of estradiol and progesterone were reintroduced in 23 women. Cognitive tests were administered during each hormone condition. To evaluate possible practice effects arising during repeated testing, an identical battery of tests was administered at the same time intervals in 11 untreated women. With the exception of an improved performance on mental rotation during estradiol, we observed no significant effects of estradiol or progesterone on measures of attention, concentration, or memory compared with hypogonadism. In contrast to studies in which a decline in cognitive performance was observed in women receiving ovarian suppression therapy for an underlying gynecologic condition, we confirm a prior report demonstrating that short-term changes in gonadal steroids have a limited effect on cognition in young, healthy women. Differences in the clinical characteristics of the women receiving GnRH agonists could predict a risk for ovarian steroid-related changes in cognitive performance during induced, and possibly, natural menopause.
authors.affiliation: Section on Behavioral Endocrinology, National Institute of Mental Health, National Institutes of Health, Department of Health & Human Services, Bethesda, MD 20892-1277, USA. PeterSchmidt@mail.nih.gov
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Schmidt
authors.forename: P A
authors.initials: PA
authors.lastname: Keenan
authors.forename: Linda A
authors.initials: LA
authors.lastname: Schenkel
authors.forename: Kate
authors.initials: K
authors.lastname: Berlin
authors.forename: Carolyn
authors.initials: C
authors.lastname: Gibson
authors.forename: David R
authors.initials: DR
authors.lastname: Rubinow
mesh_terms: D000328:Adult; D001288:Attention / Q000187:drug effects; D016022:Case-Control Studies; D003071:Cognition / Q000187:drug effects*; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage; D020249:Hormone Replacement Therapy; D006801:Humans; D007006:Hypogonadism / Q000097:blood / Q000139:chemically induced* / Q000503:physiopathology / Q000523:psychology*; D007273:Injections, Intramuscular; D016729:Leuprolide / Q000494:pharmacology*; D008568:Memory / Q000187:drug effects; D010053:Ovary / Q000187:drug effects*; D017697:Premenopause; D011374:Progesterone / Q000494:pharmacology*; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data
chemical_list: D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D016729:Leuprolide